ESC 2022 – Novo’s cardiovascular charge continues

ESC 2022 – Novo’s cardiovascular charge continues

Source: 
EP Vantage
snippet: 

Novo Nordisk has become a $200bn company by focusing primarily on diabetes. But in an apparent admission that it needs more spokes to its wheels, the group has been expanding its horizons of late with deals in cardiovascular and rare diseases.

The recent ESC meeting featured a couple of the Danish company’s heart disease contenders, with mid-stage data on the anti-IL-6 project ziltivekimab, and long-awaited details on a phase 2 study of PRX004 in amyloidosis with cardiomyopathy. However, it has not all been plain sailing: after Covid delayed the start of first-in-human trials of the stem cell candidate HS-001, dosing is set to finally get under way this year.